CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.3800
-0.0900 (-2.59%)
As of 11:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.4700
Open3.4600
Bid3.3800 x 1100
Ask3.3900 x 2200
Day's Range3.3594 - 3.4734
52 Week Range2.1800 - 4.5100
Volume376,475
Avg. Volume639,312
Market Cap346.785M
Beta (3Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.2230
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX) Shift From Loss To Profit
    Simply Wall St.27 days ago

    Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX) Shift From Loss To Profit

    Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX): Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. The US$318.1m market-cap postedRead More...

  • GlobeNewswire27 days ago

    Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York City Cantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES, Fla., ...

  • Catalyst (CPRX) Up 16% Since Last Earnings Report: Can It Continue?
    Zackslast month

    Catalyst (CPRX) Up 16% Since Last Earnings Report: Can It Continue?

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
    SmarterAnalyst2 months ago

    Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks

    Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 20th Annual Global Investment Conference, which is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3.

  • Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock
    SmarterAnalyst2 months ago

    Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock

    Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company's flagship candidate Firdapse approved, but they may not have to wait much longer -- the FDA is expected to make a decision by November 28. Catalyst had previously submitted an NDA for Firdapse off one positive pivotal trial in Lambert-Eaton myasthenic syndrome (LEMS). While the company believed this single trial, together with other information, would be adequate for approval, the FDA issued a Refuse-to-File letter in early 2016.

  • ACCESSWIRE2 months ago

    Catalyst Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM ...

  • Associated Press2 months ago

    Catalyst: 2Q Earnings Snapshot

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    CORAL GABLES, Fla., Aug. 07, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Expands Commercial Leadership Team

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team. Catalyst has appointed Jason James as Senior Vice President of Commercial Operations & Analytics, Jeff Del Carmen as Senior Vice President of Sales and Marketing, Kevin Rohrbach as Senior Director of Patient Engagement/Advocacy, and Maria Pandolfo as Senior Director of Patient Services.  Catalyst has also added three Senior Medical Science Liaisons (MSL) to its team, bringing the total of its MSL’s to five.

  • GlobeNewswire3 months ago

    Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 8th, 2018

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Wednesday, August 8, 2018 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ladder ...

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

    WallStEquities.com revisits the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Under assessment this morning are these four stocks: Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).

  • ACCESSWIRE4 months ago

    Free Research Reports on Catalent and Three More Generic Drugs Stocks

    Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.

  • ACCESSWIRE5 months ago

    Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGRX as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted final approval to the Company's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Active-Investors.com is currently working on the research report for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), which also belongs to the Healthcare sector as the Company Eagle Pharma.

  • Associated Press5 months ago

    Catalyst: 1Q Earnings Snapshot

    The Coral Gables, Florida-based company said it had a loss of 6 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...